Autopsy report · NCT05081388
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Ran for about 8 months before it stopped.
- 25 participants enrolled.
- Results were posted on the registry 1 year 10 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- SARS-CoV-2
- Interventions
- REGN14256; imdevimab; casirivimab + imdevimab; Placebo
- Participants
- 25
- Sites
- 28
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.